Real-world experience with mavacamten in obstructive hypertrophic cardiomyopathy: Observations from a tertiary care center

Abstract

In a real-world study in symptomatic oHCM patients at a multi-hospital tertiary care referral center, we demonstrate the efficacy and safety, along with the logistic feasibility of prescribing mavacamten under the REMS program.